Company profile: Luminary Therapeutics
1.1 - Company Overview
Company description
- Provider of preclinical cell therapies for cancer and autoimmune diseases, including the Allogeneic Gamma 2.0+ platform for B-cell malignancies; Split Co-Stim Dual CAR targeting multiple solid tumor antigens, designed to enhance persistence and prevent T cell exhaustion; BAFF ligand-based CAR addressing BAFF, BCMA, and TACI to mitigate antigen escape; and a non-viral TcBuster transposon process for cost-efficient CAR-T manufacturing.
Products and services
- Allogeneic Gamma 2.0+ Platform: Engineers an allogeneic platform to develop cell therapy products for B-cell malignancies and autoimmune diseases, improving persistence and durability while lowering costs
- Non-Viral Gene Modification Process: Produces transposon-based CAR-T manufacturing by leveraging the TcBuster system for stable integration of large genetic cargo, reducing engineering costs
- BAFF Ligand Based CAR: Develops a multi-antigen CAR T assembly targeting BAFF, BCMA, and TACI for B-cell malignancies and autoimmune diseases, mitigating antigen escape
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Luminary Therapeutics
GlobeImmune
HQ: United States
Website
- Description: Provider of a proprietary Tarmogen® platform used to develop products for the treatment of cancer and infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GlobeImmune company profile →
Affimed
HQ: Germany
Website
- Description: Provider of innate cell engager (ICE) antibody therapeutics for cancer, including AFM13 (CD30/CD16A), AFM24 (EGFR-directed engaging NK cells and macrophages), and AFM28 (CD123/CD16A for AML), plus the ROCK platform for customizable ICEs, ongoing clinical trials, and partnerships with pharmaceutical companies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Affimed company profile →
NexImmune
HQ: United States
Website
- Description: Provider of immuno-therapeutics using proprietary AIM artificial immune technology, including AIM ACT, a cellular therapy using AIM nanoparticles to orchestrate specific T cell functions for cancer treatment; AIM INJ, an injectable AIM nanoparticle product targeting disease-specific T cells; and Phase 1/2 candidates NEXI-001 (AML) and NEXI-002 (multiple myeloma).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NexImmune company profile →
Calidi Biotherapeutics
HQ: United States
Website
- Description: Provider of clinical-stage cancer immunotherapies based on stem cell-delivered oncolytic viruses. Programs include NeuroNova (neural stem cells + oncolytic adenovirus) for glioblastoma; SuperNova (adipose-derived mesenchymal stem cells + oncolytic vaccinia) for advanced solid tumors; RTNova, a systemic enveloped oncolytic virotherapy; CLD-101 in Phase 1 for recurrent high-grade glioma; and CLD-201, a cell-based virotherapy planned for Phase 1.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calidi Biotherapeutics company profile →
BlueSphere Bio
HQ: United States
Website
- Description: Provider of TCXpress technology designed to unlock the potential of personalized T-cell therapy for the treatment of cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlueSphere Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Luminary Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Luminary Therapeutics
2.2 - Growth funds investing in similar companies to Luminary Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Luminary Therapeutics
4.2 - Public trading comparable groups for Luminary Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →